ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Portland, OR, USA:

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: carboplatin
Drug: paclitaxel

Phase 2

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 41 other locations

be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...

Active, not recruiting
Recurrent Epithelial Ovarian Cancer
Recurrent Peritoneal Cancer
Other: DPX-Survivac
Drug: Cyclophosphamide

Phase 1, Phase 2

Immunovaccine

Portland, Oregon, United States and 8 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Portland, Oregon, United States and 46 other locations

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...

Enrolling
Low Grade Serous Ovarian Cancer
Drug: Defactinib
Drug: Letrozole

Phase 3

Verastem

Portland, Oregon, United States and 53 other locations

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer...

Enrolling
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Drug: Luveltamab tazevibulin
Drug: Gemcitabine

Phase 2, Phase 3

Sutro Biopharma

Portland, Oregon, United States and 38 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Active, not recruiting
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 3

Mural Oncology

Portland, Oregon, United States and 117 other locations

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus...

Active, not recruiting
Primary Peritoneal Cancer
Epithelial Ovarian Cancer
Biological: IMNN-001
Drug: Carboplatin

Phase 1, Phase 2

IMUNON
IMUNON

Portland, Oregon, United States and 20 other locations

of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with hig...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Phase 2

ImmunoGen
ImmunoGen

Portland, Oregon, United States and 77 other locations

Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...

Active, not recruiting
Ovarian Neoplasms
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Drug: Dostarlimab-Placebo
Drug: Standard of care

Phase 3

Tesaro
Tesaro

Portland, Oregon, United States and 202 other locations

cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian...

Active, not recruiting
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Drug: Paclitaxel
Biological: Placebo

Phase 3

CanariaBio

Portland, Oregon, United States and 148 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems